Health Care [ 9/12 ] | Biotechnology [ 38/73 ]
NASDAQ | Common Stock
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors.
In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease.
Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A.
The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx.
Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 25 | 0.31 Increased by +6.90% | 0.20 Increased by +55.00% |
| Feb 12, 25 | 0.84 Increased by +500.00% | 0.28 Increased by +200.00% |
| Nov 6, 24 | 0.29 Decreased by -36.96% | 0.33 Decreased by -12.12% |
| Aug 8, 24 | 0.32 Increased by +6.67% | 0.32 |
| May 2, 24 | 0.29 Increased by +480.00% | 0.14 Increased by +107.14% |
| Feb 14, 24 | 0.14 Increased by +7.69% | 0.30 Decreased by -53.33% |
| Nov 7, 23 | 0.46 Decreased by -13.21% | 0.31 Increased by +48.39% |
| Aug 3, 23 | 0.30 Decreased by -25.00% | 0.29 Increased by +3.45% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 4.93 B Increased by +19.06% | 195.00 M Decreased by -85.28% | Increased by +3.95% Decreased by -87.64% |
| Dec 31, 24 | 6.44 B Increased by +37.69% | 3.85 B Increased by +500.78% | Increased by +59.70% Increased by +336.34% |
| Sep 30, 24 | 5.54 B Increased by +16.78% | 1.27 B Decreased by -39.83% | Increased by +22.85% Decreased by -48.47% |
| Jun 30, 24 | 5.40 B Increased by +28.68% | 1.41 B Increased by +5.47% | Increased by +26.06% Decreased by -18.04% |
| Mar 31, 24 | 4.14 B Increased by +45.16% | 1.32 B Increased by +530.95% | Increased by +31.98% Increased by +334.65% |
| Dec 31, 23 | 4.68 B Decreased by -10.50% | 640.00 M Increased by +9.59% | Increased by +13.68% Increased by +22.45% |
| Sep 30, 23 | 4.74 B Increased by +16.08% | 2.10 B Decreased by -18.51% | Increased by +44.35% Decreased by -29.80% |
| Jun 30, 23 | 4.20 B Increased by +32.76% | 1.33 B Decreased by -29.40% | Increased by +31.80% Decreased by -46.82% |